Article Text

Download PDFPDF

Correction: Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study

Statistics from Altmetric.com

Shen L, Guo J, Zhang Q, et al. Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study. J immunother Cancer 2020;8:e000437. doi: 10.1136/jitc-2019-000437

Since the online publication of this article, the authors have noticed that the author name Zuobai Wang was incorrectly spelt as Zoubai Wang. This has been corrected.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.